Intestinal cancer

Summary

Intestinal cancer (MONDO:0005814) is a cancer (an umbrella term covering 6 Mondo subtypes) with 1 cohort gene and 28 clinical trials. Top therapeutic interventions include artesunate, bisacodyl, and cipepofol.

At a glance

• Classification: Cancer
• Umbrella term: 6 Mondo subtypes
• Cohort genes: 1
• Clinical trials: 28

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intestinal cancer
Mondo ID	MONDO:0005814
EFO	EFO:0007330
MeSH	D007414
DOID	DOID:10155
ICD-11	150210507
NCIT	C4572
SNOMED CT	363508008
UMLS	C0346627
MedGen	87562
Anatomy (UBERON)	UBERON:0000160
Is cancer (heuristic)	yes

Also known as: bowel cancer · cancer of intestine · cancer of the intestine · intestinal cancer · intestinal neoplasms, malignant · intestinal tumors, malignant · intestine cancer · malignant intestinal neoplasm · malignant intestinal neoplasms · malignant intestinal tumor · malignant intestinal tumors · malignant intestinal tumour · malignant intestinal tumours · malignant intestine neoplasm · malignant intestine tumor · malignant intestine tumour · malignant neoplasm of intestine · malignant neoplasm of the intestine · malignant tumor of intestine · malignant tumor of the intestine (+2 more)

Data availability: 1 GenCC gene-disease record.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › intestinal cancer

Related subtypes (14): gastric cancer, jaw cancer, liver cancer, gastrointestinal lymphoma, gallbladder cancer, oral cavity cancer, pharynx cancer, spleen cancer, digestive system carcinoma, esophageal cancer, malignant pancreatic neoplasm, malignant tumor of floor of mouth, digestive system melanoma, gastroesophageal cancer

Subtypes (6): anal canal cancer, small intestine cancer, intestine carcinoma in situ, gastric intestinal type adenocarcinoma, colorectal cancer, colorectal Kaposi sarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 16 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
SDHD	Limited	Autosomal dominant	intestinal cancer	16

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SDHD	Orphanet:100093	Carcinoid syndrome
SDHD	Orphanet:201	Cowden syndrome
SDHD	Orphanet:276621	Sporadic pheochromocytoma/secreting paraganglioma
SDHD	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
SDHD	Orphanet:3208	Isolated succinate-CoQ reductase deficiency
SDHD	Orphanet:97286	Carney-Stratakis syndrome

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SDHD	HGNC:10683	ENSG00000204370	O14521	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SDHD	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial	Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SDHD	Other/Unknown	no		CybS, SQR/QFR_C/D

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
jejunal mucosa	1
jejunum	1
rectum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SDHD	287	ubiquitous	marker	jejunal mucosa, rectum, jejunum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SDHD	2,229

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SDHD	O14521	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 3. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Maturation of TCA enzymes and regulation of TCA cycle	1	571.0×	0.004	SDHD
Citric acid cycle (TCA cycle)	1	423.0×	0.004	SDHD
Respiratory electron transport	1	95.2×	0.011	SDHD

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of catecholamine secretion	1	16852.0×	3e-04	SDHD
mitochondrial electron transport, succinate to ubiquinone	1	3370.4×	7e-04	SDHD
tricarboxylic acid cycle	1	510.7×	0.003	SDHD
proton motive force-driven mitochondrial ATP synthesis	1	263.3×	0.005	SDHD
cellular response to hypoxia	1	121.2×	0.008	SDHD

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Fluorouracil	Phase 3 (in late-stage trials)
Simvastatin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alectinib, Artesunate.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SDHD	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	SDHD

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SDHD	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 28.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	22
PHASE2	2
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01887158	PHASE4	COMPLETED	Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection
NCT03350490	PHASE2/PHASE3	COMPLETED	Bioinformation Therapy for Intestinal Cancer
NCT07095309	PHASE2	NOT_YET_RECRUITING	Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer
NCT07341737	PHASE1/PHASE2	NOT_YET_RECRUITING	SL-28 for Advanced Solid Tumours
NCT02633098	PHASE2	UNKNOWN	A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer
NCT02662348	PHASE1	UNKNOWN	T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
NCT05853094	Not specified	RECRUITING	Postoperative Effects of Different Enterostomy Approaches
NCT06267378	Not specified	RECRUITING	Assessing Frailty and Its Impacts on Patients Facing Major GI Surgery
NCT06979882	Not specified	NOT_YET_RECRUITING	Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Intestinal Carcinoma
NCT06981182	Not specified	NOT_YET_RECRUITING	EQUITA - A Feasibility Trial of a Faith-placed Intervention to Increase Screening Uptake in Black Adults
NCT07341126	Not specified	NOT_YET_RECRUITING	Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal
NCT01868971	Not specified	COMPLETED	Clinical Study to Establish the Feasibility and Usability of the EndoRings™
NCT02200055	Not specified	COMPLETED	Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need
NCT02208401	Not specified	COMPLETED	Randomised Comparison of 2 Cold Snare Polypectomy Techniques
NCT03479645	Not specified	COMPLETED	Serial SMS Reminders and an Opt-out Mailed FIT Kits to Improve Colorectal Screening Participation: A Single Center RCT
NCT03563586	Not specified	UNKNOWN	Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery
NCT04659590	Not specified	COMPLETED	Exploratory Study of Rectal Mucus for Diagnosing Disease
NCT04747665	Not specified	UNKNOWN	Experiences and Perceptions of Colonoscopy and New Technologies
NCT05032794	Not specified	COMPLETED	Unrestricted Diet for Screening Colonoscopy
NCT05043363	Not specified	COMPLETED	LuCID - Investigating the Use of a Novel Digital Rectoscope for Community Examinations During COVID-19
NCT05110378	Not specified	COMPLETED	Do Good Non-Technical Skills Correlate With Good Clinical Outcomes in Endoscopy?
NCT05510388	Not specified	UNKNOWN	HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients
NCT05517408	Not specified	UNKNOWN	Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
NCT05526339	Not specified	UNKNOWN	HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
NCT05809661	Not specified	COMPLETED	Implementation of the Nurse Navigation Program
NCT06008847	Not specified	COMPLETED	Capsule Endoscopy Delivery at sCale Through Enhanced AI anaLysis Study
NCT06106165	Not specified	COMPLETED	Improving Muslim Women’s Uptake of Cancer Screening (IMCAN)
NCT06219395	Not specified	UNKNOWN	Capsule Endoscopy in Iron Deficiency Anaemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ARTESUNATE	4	2
BISACODYL	4	2
CIPEPOFOL	3	1
POLYETHYLENE GLYCOL	3	1